Mabwell Shanghai Bioscience Co Ltd
SSE:688062
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (3.5), the stock would be worth ¥33.28 (7% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.8 | ¥35.73 |
0%
|
| 3-Year Average | 3.5 | ¥33.28 |
-7%
|
| 5-Year Average | 3.4 | ¥31.93 |
-11%
|
| Industry Average | 5.3 | ¥49.64 |
+39%
|
| Country Average | 1.9 | ¥18.15 |
-49%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
M
|
Mabwell Shanghai Bioscience Co Ltd
SSE:688062
|
14.3B CNY | 3.8 | -15.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 4.5 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 3.6 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 3.7 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 7.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 1.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Mabwell Shanghai Bioscience Co Ltd
Glance View
Mabwell Shanghai Bioscience Co Ltd is an emerging player in the biotechnology landscape, harnessing the power of scientific innovation to carve a niche in the biopharmaceutical industry. Established in the bustling hub of Shanghai, the company is at the forefront of developing novel therapeutics, focusing primarily on monoclonal antibodies and recombinant proteins. Mabwell's operations are centered around an integrated approach to drug development, combining rigorous in-house research with strategic partnerships to expedite the journey from discovery to market. This approach enables the company to address unmet medical needs in a variety of therapeutic areas, including oncology, autoimmunity, and infectious diseases. Revenue streams for Mabwell are generated through a blend of proprietary product sales, collaborative research agreements, and licensing deals. By anchoring their business model in these multiple channels, the company not only spreads its risk but also capitalizes on diverse opportunities within the global biotech sphere. With a robust pipeline of biotherapeutics in various stages of clinical development, Mabwell strategically positions itself to establish long-term value and competitive advantage. Its commitment to cutting-edge research and development, coupled with a keen eye for market demands, underscores Mabwell's ambition to become a significant contributor to the biotechnology industry.
